MARKET

NOVN

NOVN

Novan
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.68
+5.64
+62.39%
After Hours: 14.30 -0.38 -2.59% 19:59 06/11 EDT
OPEN
14.36
PREV CLOSE
9.04
HIGH
18.68
LOW
13.60
VOLUME
126.34M
TURNOVER
--
52 WEEK HIGH
25.90
52 WEEK LOW
3.000
MARKET CAP
222.71M
P/E (TTM)
-5.4544
1D
5D
1M
3M
1Y
5Y
Hot Stocks: big moves for experimental drugs, Didi stock coming to America, RBC likes ZM, CHWY earnings
monsitj/iStock via Getty Images Drug development was a major theme on Friday, with several stocks making big moves in response to pipeline-altering news for their experimental products. This included Noven
Seekingalpha · 1d ago
Stocks That Hit 52-Week Highs On Friday
    During Friday's morning session, 236 stocks hit new 52-week highs.
Benzinga · 1d ago
VXRT, NOVN, HTBX and CRIS among midday movers
Gainers: Novan (NOVN) +74%.Urban One (UONE) +39%.Iconix Brand (ICON) +28%.Aptinyx (APTX) +24%.Carver Bancorp (CARV) +22%.Vaxart (VXRT) +21%.Xinyuan Real Estate (XIN) +20%Broadway Financial (BYFC) +18%.Amesite (AMST) +18%.Siebert Financial (SIEB) +16%.Loser...
Seekingalpha · 2d ago
Novan, Vaxart leads healthcare gainers; Orphazyme, Curis among major losers
Gainers: Novan (NOVN) +81%, Aptinyx (APTX) +25%, Vaxart (VXRT) +39%, Progenity (PROG) +28%, Chemomab Therapeutics (CMMB) +9%.Losers: Orphazyme (ORPH) -41%, Curis (CRIS) -32%, Aptose Biosciences (APTO) -30%, Galecto (GLTO) -22%, Heat Biologics (HTBX) -23%.
Seekingalpha · 2d ago
A Technical Look At Novan's Stock Amid 80% Spike
Novan Inc. (NASDAQ: NOVN) shares are trading higher Friday after the company reported that B-SIMPLE4 pivotal Phase 3 trial of SB206 achieved significance for the primary endpoint with no adverse events.
Benzinga · 2d ago
Why Novan Shares Are Surging Today
Novan Inc (NASDAQ: NOVN) shares are trading higher by 59% at $14.37 Friday morning after the company reported the B-SIMPLE4 pivotal Phase 3 trial of SB206 achieved statistical significance for the primary endpoint and no serious adverse events were reporte...
Benzinga · 2d ago
Hot Stocks: Tesla makes Plaid sexy, big drug development moves, PLAY gets play
primeimages/E+ via Getty Images Tesla (TSLA) was in the spotlight Friday following the formal launch of its latest electric car model. At the same time, a handful of stocks posted
Seekingalpha · 2d ago
Thinking about buying stock in Novan, Chemomab Therapeutics, Precigen, ChemoCentryx, or Senseonics?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NOVN, CMMB, PGEN, CCXI, and SENS.
PR Newswire - PRF · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NOVN. Analyze the recent business situations of Novan through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NOVN stock price target is 35.00 with a high estimate of 45.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 56
Institutional Holdings: 2.11M
% Owned: 13.91%
Shares Outstanding: 15.17M
TypeInstitutionsShares
Increased
7
24.32K
New
19
414.76K
Decreased
5
186.88K
Sold Out
6
35.17K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.92%
Pharmaceuticals & Medical Research
-0.72%
Key Executives
Chairman/President/Chief Executive Officer/Director
Paula Stafford
Chief Financial Officer/Vice President - Finance/Controller/Secretary
John Gay
Lead Director/Independent Director
W. Geer
Chief Executive Officer/Director
G Kelly Martin
Director
James Bierman
Independent Director
Robert Ingram
Independent Director
Robert Keegan
Independent Director
John Palmour
Independent Director
Machelle Sanders
Independent Director
Steven Skolsky
No Data
About NOVN
Novan, Inc. is a clinical development-stage biotechnology company. The Company is focused on leveraging nitric oxide’s naturally occurring anti-microbial and immunomodulatory mechanisms of action to treat a range of diseases. The Company has created a Nitricil technology platform enabling the development of new chemical entities (NCEs) with delivery of nitric oxide. The Company’s two key components of its nitric oxide platform are its Nitricil technology, which drives the creation of NCEs, and its formulation science, both of which it uses to tune its product candidates for specific indications. Novan’s Nitricil technology enables it to store large amounts of nitric oxide gas in a stable, solid form by chemically loading it on a macromolecule, or polymer. The nitric oxide platform has produced a portfolio that includes the various clinical stage dermatology product candidates: SB204, SB206, SB208 and SB414.

Webull offers kinds of Novan Inc stock information, including NASDAQ:NOVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NOVN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NOVN stock methods without spending real money on the virtual paper trading platform.